Clorox Co: Form 10-Q for the period ended Dec 31, 2023
Filed with the SEC on Feb 1, 2024 and accepted by EDGAR at Feb 1, 2024, 16:45 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-10-01 to 2023-12-31 | $1.99bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-07-01 to 2023-12-31 | $3.38bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-10-01 to 2023-12-31 | $1.12bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-07-01 to 2023-12-31 | $1.98bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-10-01 to 2023-12-31 | $866.0m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-07-01 to 2023-12-31 | $1.40bn | us-gaap:GrossProfit |
| Research and development | 3 months2023-10-01 to 2023-12-31 | $32.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-07-01 to 2023-12-31 | $61.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-10-01 to 2023-12-31 | $322.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-07-01 to 2023-12-31 | $598.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2023-10-01 to 2023-12-31 | $26.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-07-01 to 2023-12-31 | $47.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-10-01 to 2023-12-31 | $40.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-07-01 to 2023-12-31 | $44.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-10-01 to 2023-12-31 | $93.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-07-01 to 2023-12-31 | $115.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-10-01 to 2023-12-31 | $0.75 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-07-01 to 2023-12-31 | $0.92 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-10-01 to 2023-12-31 | $0.75 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-07-01 to 2023-12-31 | $0.93 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-10-01 to 2023-12-31 | 124,620,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-07-01 to 2023-12-31 | 124,635,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-07-01 to 2023-12-31 | $173.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-07-01 to 2023-12-31 | $76.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2023-07-01 to 2023-12-31 | $298.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2023-12-31 | $355.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $1.80bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $5.91bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $2.02bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $5.69bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $2.48bn | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2023-12-31 | $247.0m | us-gaap:CommercialPaper |
| Shareholders' equity | At period end2023-12-31 | $53.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000021076-24-000010. Last ingested by Listed: Nov 5, 2026, 18:00 ET. Listed shows no prices and gives no investment advice.